

Communication

Engineered PQQ-glucose dehydrogenase as a universal biosensor platform

Zhong Guo, Lindy Murphy, Viktor Stein, Wayne Johnston, Siro Alcala Perez, and Kirill Alexandrov

J. Am. Chem. Soc., **Just Accepted Manuscript** • DOI: 10.1021/jacs.6b06342 • Publication Date (Web): 27 Jul 2016

Downloaded from <http://pubs.acs.org> on July 28, 2016

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



Engineered PQQ-glucose dehydrogenase as a universal biosensor platform

Zhong Guo^[1], Lindy Murphy^[2], Viktor Stein^[1], Wayne A Johnston^[1], Siro Alcala Perez^[2] and Kirill Alexandrov^{[1]*}

^[1] Institute for Molecular Bioscience and Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4072, Australia, E-mail: k.alexandrov@uq.edu.au, ^[2] Molecular Warehouse Ltd, 40 Occam Road, Guildford, GU2 7YG, UK

ABSTRACT: Biosensors with direct electron output hold the promise of nearly seamless integration with portable electronic devices. However, so far they were based on naturally occurring enzymes that significantly limits the spectrum of detectable analytes. Here we present a novel biosensor architecture based on analyte driven intermolecular recombination and activity reconstitution of reengineered component of glucometers: PQQ-glucose dehydrogenase. We demonstrate that this sensor architecture can be rapidly adopted to the detection of immunosuppressant drugs, α -amylase protein or protease activity of thrombin and Factor Xa. The biosensors could be stored in dried form without the appreciable loss of activity. We further show that ligand-induced activity of the developed biosensors could be directly monitored by chronoamperometry enabling construction of disposable sensory electrodes. We expect that this architecture could be expanded to the detection of other biochemical activities, posttranslational modifications, nucleic acids and inorganic molecules.

The ability to rapidly monitor the concentrations and activities of biomolecules in complex samples is a key requirement in medicine, life sciences and biotechnology. Protein-based biosensors have been used extensively to develop analytical and diagnostic applications. The increasing demand for Point-of-Care (POC) applications creates additional pressure to develop rapid, inexpensive, durable and sensitive sensors capable of detecting multiple analytes¹. Among all available readout systems electrochemical sensors feature prominently due to their simplicity and specificity². Electrochemical blood glucose sensors account for nearly 90% of the US\$15 billion global biosensor market³. Screen printed disposable electrodes functionalised with glucose dehydrogenase (GDH) or

glucose oxidase are now ubiquitous and can be manufactured for less than \$0.1 in a continuous screen printing process⁴. The electron current generated by the biosensor enables its connectivity with portable electronic devices such as smart phones via inexpensive electronic adaptors. Remarkably, this technological and commercial success has not been paralleled by other electrochemical biosensors despite the need for better and cheaper diagnostics and analytics in many industries. While GDH has been used extensively to create new biosensor applications, this was achieved either by using the enzyme as a reporter in ELISA type assays or by developing glucose-generating signalling circuits that ultimately activate GDH and induce electron flow^{5,6}. The high current generated by this class of enzymes also enabled their use in implantable biofuel cells⁷. Recently we engineered a PQQ-GDH-calmodulin chimera that functions as a Ca^{2+} biosensor⁸. Although the developed biosensor could be used for quantification of Ca^{2+} in biological samples and performed well when manufactured into a sensory electrode, the developed sensory architecture was not generic. Domain insertion is an inherently empiric process that relies on large conformational change of the sensory domain⁹. Such domains are readily available for only a few analytes and their engineering is far from trivial¹⁰.

Analysis of the properties of the previously reported Ca^{2+} -sensing Calmodulin-GDH chimera convinced us that GDH was a suitable building block for construction of synthetic electrochemical receptors. Its excellent physical stability combined with very high catalytic rate (k_{cat} 3860 per second) makes it an ideal actuator for direct interfacing with electronic devices¹¹. The observation that the loop connecting strands A and B of the β -sheet 3 could tolerate insertion of large domains⁸ prompted us to test whether the enzyme

could be split at this position and used to construct a two component sensory system (Fig. 1A). To this end we expressed N and C-terminal portions of the enzyme in *E. coli* in fusion with FRB and FKBP domains that form a complex in presence of rapamycin. While the FRB-GDH₁₋₁₅₃ could be produced and purified to homogeneity, the FKBP-GDH₁₅₅₋₄₅₄ formed inclusion bodies and could not be obtained in soluble form. This is not entirely surprising given the fact

recovered. We then digested the protease cleavage site in the loop connecting N- and C-fragments of GDH and repeated the reconstitution experiment. As in the previous case little GDH activity was recovered. However when the system was exposed to rapamycin we observed rapid and dose dependent recovery of GDH activity indicating that the inactivated N-terminal fragment of GDH was displaced by the FRB-fused GDH₁₋₁₅₃ fragment (Fig. 1C). We titrated the reaction with




Figure 1. Converting PQQ-GDH into a two-component biosensor. (A) Strategy for splitting GDH into two inactive halves by disrupting the loop between β -strands A and B. The activity of the enzyme is then reconstituted by the ligand-mediated scaffolding (B) an extension of the strategy shown in A where the active site residues harboured by the N-terminal fragment are mutated to alanine and the loop connecting β -strands A and B are proteolysed upon enzyme purification. (C) Change in the activity of the split GDH enzyme bearing rapamycin binding domains FRB and FKBP in the presence of rapamycin, or other macrocyclic immunosuppressants such as FK506 or Cyclosporin A. The activity of the enzyme was monitored by change of 600 nm absorption of 60 μM electron acceptor dye dichlorophenolindophenol in the presence of 0.6 mM electron mediator phenazine methosulphate, 20 mM of glucose, 15 nM of FRB-GDH₁₋₁₅₃, 10 nM of inactive full length of GDH-FKBP₁₂ and 50 μM CaCl₂. (D) As in C but using increasing concentrations of rapamycin (E) Fit of the observed reaction rates obtained in D to a quadratic equation (see SI for details).

that the split exposes the hydrophobic core of the protein. Due to compromised integrity and stability split proteins generally perform much better in vivo than in vitro, presumably due to the presence of chaperon systems the former¹². However, we found potential in the fact that the N-terminal fragment of GDH was physically stable and apparently folded autonomously. We therefore conjectured that if the C-terminal fragment could be stabilised in solution we might be able to proceed with our original plan. To this end we constructed a variant of GDH with the TVMV cleavage site in the loop connecting strands A and B and carrying a FKBP domain on its C-terminus. We also mutated the catalytically important residues Gln76, Asp143 and His144 in the active site to Ala rendering the fusion protein catalytically dead (Fig. 1B). The resulting recombinant protein was soluble and displayed no detectable catalytic activity. When the fusion protein was mixed with the purified FRB-GDH₁₋₁₅₃ in the presence and in the absence of rapamycin little activity was

increased concentrations of rapamycin and fitted the observed rates to a K_d value of 11 nM that is very close to the previously published value (Fig. 1D,E)¹³. In the fully activated state the resulting biosensor displayed approximately 20% of the catalytic rate of the wt enzyme (Fig. S1). However due to the very high turnover rate of the parental enzyme it was possible to obtain satisfactory response to low nM concentrations of the analyte on the minute scale (Fig. 1B and S1). Importantly, the reaction was specific as the excess of the related immunosuppressant compounds such as FK506 or cyclosporine did not activate the biosensor to an appreciable degree (Fig. 1C).

We next tested whether the developed sensor architecture was sufficiently generic and could be expanded onto the other small molecules and biomarkers. As rapamycin belongs to the class of clinically important macrocyclic immunosuppressants together with cyclosporine and FK506 that do not cross react with the developed biosensor we wondered if

similar biosensors could be developed for these drugs as well. We were additionally motivated by the fact that the immunosuppressants have a very narrow therapeutic window and no POC test for these compounds currently exist¹⁴. We analysed the available co-crystal structures of cyclosporine with calcinurin A and B and peptidyl-prolyl cis-trans isomerase (cyclophilin) (PDB:1MF8) and FK506 in complex with calcinurin A and B and FKBP (PDB:1TCO). The topology of the complex allowed us to design fusion proteins of GDH fragments that were expected to come into the molecular proximity when the complex assembly is induced by a ligand. The fusion proteins were produced in recombinant and purified form (Table S1) and their mixtures responded to the cognate drug in the dose dependent manner (Fig. 2A and S2). These results demonstrate that the developed biosensor architecture could be rapidly adopted to detection of xenobiotics




Figure 2 Developing biosensors for cyclosporin A and FK506 (A) activation of the Cyclosporin A biosensor (15nM N-terminal GDH-Calβ/Calα complex and 10nM inactive CYPA - GDH fusion) by cyclosporin but not FK506 or rapamycin (B) As in A and D but using FK506 biosensor (15nM N-terminal GDH-Calβ/Calα complex and 10nM inactive CYPA-GDH fusion) .

with known targets.

In the next step we wanted to test whether the developed biosensor architecture could be applied to the detection of protein biomarkers. As the first example we chose human stress biomarker salivary α -amylase. We analysed the available crystal structures of α -amylase and identified three crystal structures of porcine α -amylase. Based on structural analysis of α -amylase bound to VHH domains (PDB: 1KXQ, 1KXT, 1KXV and 1BVN), we constructed fusion proteins with GDH₁₋₁₅₃-VHH_{1KXV} and GDH inactive mutant with insertion of VHH_{1BVN} and produced them in recombinant form (Fig.3A). Addition of human salivary α -amylase to the mixture of both recombinant proteins resulted in a dose dependent increase in GDH activity that decreased at higher concentration reflecting formation of alpha amylase complexes with only one fusion protein bound to it (Fig.3B,C). These results demonstrate that the developed sensory architecture could be used for the detection of protein biomarkers.

Finally we wanted to establish whether the developed sensor architecture could be used to measure enzymatic activities such as proteolysis rather than molecular entities. In order to connect the protease activity to reconstitution of GDH from fragments we created an autoinhibited version of SH3 domain in which an SH3 domain binding peptide was linked to SH3 domain via protease - digestible linker (Fig.3E). In this configuration SH3 domain is protected from the binding of

an external SH3 domain binding peptide as long as the linker connecting the domain and its ligand is intact. We fused the autoinhibited SH3 module to GDH₁₋₁₅₃ C-terminally while SH3 peptide was inserted into inactive full-length GDH with protease cleavage site at its N-terminal. In this design we placed a Factor Xa cleavage site between the SH3 domain and its ligand, and as well as between inactive N-terminal of GDH₁₋₁₅₃ and SH3 binding peptide. When the solution of the constructs produced in the recombinant form were mixed together, only low level GDH activity could be detected suggesting that SH3 peptide was not able to drive enzyme reconstitution. However, addition of Factor Xa resulted in time dependent increase of GDH activity indicating that proteolytic removal of the auto-inhibitory peptide enables binding of the SH3 peptide in trans and reconstitution of the active complex (Fig. 3F).




Figure 3. Adapting the developed biosensory architecture to detection of proteins and enzymatic activities. (A) Schematic representation of a two component α -Amylase (α -am) biosensor. (B) Change in enzymatic activity of the biosensor at different concentrations of α -amylase. 30nM of GDH₁₋₁₅₃-VHH_{1KXV} and 20nM of inactive of full-length GDH with VHH_{1BVN}-insertion were used in the assay. (C) A plot of the observed rates against the concentration of amylase used (E) Schematic representation of a protease biosensor based on GDH where reconstitution is driven by the interaction of the SH3 domain with its ligand peptide (SH3L). (F) The increase in GDH activity of the factor Xa biosensor in the presence of increasing concentrations of Xa protease. 15nM of fusion protein GDH₁₋₁₅₃-SH3-SH3 binding peptide and 10nM of inactive of full-length GDH with insertion of SH3 binding peptide were used in the assay. (G) as in F but using the biosensor bearing a thrombin cleavage site.

In order to demonstrate the universal nature of the protease biosensor we replaced the factor Xa cleavage site with that of thrombin. We repeated the same experiment using a thrombin cleavage site and thrombin protease and observed a robust activation of the biosensor in the presence of the protease (Fig 3G). When comparing the response rate of the protease biosensor to that of immunosuppressant and amylase we noticed that the former was activated significantly slower. We suspected that this was due to the high K_m and low k_{cat} of proteases resulting in comparatively slow rates of linker digestion. Indeed incorporation of the three copies of the Factor Xa substrate sequence increased both the response

rate and the sensitivity of this biosensor presumably by reducing the complete dissociation of non-productive protease:peptide complexes. (Fig. S3).

The overwhelming success of the GDH based glucose monitors is at least in part due to the high stability of the enzyme that allows dehydration of the biosensor on the electrodes and their long term storage at ambient temperatures. To test whether the engineered versions of GDH could be desiccated and rehydrated in functional form we incubated dried rapamycin biosensor for up to 2 weeks at room temperature (Fig.S4) with no appreciable loss of activity upon reconstitution. In an alternative experiments the dried biosensor was incubated for 2 hours at different temperatures. The data shows that no activity was lost up to 40°C, and only a small reduction in activity was observed up to 50°C (Fig.S4). Next, we tested the performance of the α -amylase biosensors in chronoamperometric measurements using a commercial potentiostat. As can be seen in the figure S5A and B the biosensor generated progressively higher current when exposed to the increasing concentrations of α -amylase.

To date, only electrochemical biosensors such as the glucose monitors meet the performance and cost benchmarks for their ubiquitous deployment. The success of the glucose monitors relates to the prevalent and the debilitating nature of diabetic condition, the abundance of the analyte that simultaneously serves as a source of energy and the remarkable stability of the biosensor. Here we build on the highly advanced glucometer technology by re-engineering to its principle catalyst PQQ-GDH into a generic biosensor architecture. By exploiting the remarkable biophysical stability of the enzyme we convert it into a two component signalling system where individual components neither active nor capable of reassembly (Fig 1B). This is achieved by creating a split enzyme with inactive fragment that serves both as an inhibitor of spontaneous activation and as a chaperon factor ensuring the correct folding and stability of the active half of the enzyme. A somewhat similar strategy was recently devised to stabilise a split-fibronectin receptor system where ligand binding to its cognate fibronectin receptor drove the functional association of two split-fragments which was subsequently actuated through a fluorescent signal¹⁵. Yet, no such strategy has been devised for split-enzyme sensors that often suffer from inferior biophysical properties limiting their utility for in vitro applications as recently demonstrated for firefly luciferase¹⁶. Activation of the developed system is achieved through the analyte-mediated scaffolding of the fragments that result in the concentration driven replacement of the inactive N-terminal fragment with its active form. The kinetics of activation is surprisingly rapid, indicating high off rate of the engineered complex. The sensors demonstrated excellent response rate, sensitivity and selectivity confirming that the system is modular and can be adopted practically any analyte for which a binding domain can be found. In principle the system can be expanded to semisynthetic systems and used to detect association events mediated by small molecules, nucleic acids and other types of biological molecules and post translational modifications. This has potentially important implications as the ubiquitous presence of the internet enabled personal electronic devices

has long supported the idea of personal mobile analytic and diagnostic applications that already stimulated the efforts to create biosensors based on redox enzymes^{17,18}. The high catalytic rate of GDH-based biosensors and the resulting high electron current simplify the detection of the molecular recognition events potentially enabling electrode miniaturisation and multiplexing.

AUTHOR INFORMATION

Corresponding Author: Kirill Alexandrov
k.alexandrov@uq.edu.au

ACKNOWLEDGMENT: This work was supported in part by ARC DP grant DP150100936, DP160100973, NHMRC program grant APP1037320 and NHMRC Development grant APP113262 and by a New Concept Grant awarded through the It's a Bloke's Thing initiative and Prostate Cancer Foundation of Australia to KA. This work was also supported by the Innovate UK grant 720780 to Molecular Warehouse Ltd.

Supporting Information: Sequences and expression conditions for biosensors used in this work, assay conditions and data processing methods, supplementary figure S1-S5.

REFERENCES

- (1) Romeo, A., Leung, T. S., and Sánchez, S. Smart biosensors for multiplexed and fully integrated point-of-care diagnostics. *Lab Chip* **2016**, *16*, 1957–61.
- (2) Ronkainen, N. J., Halsall, H. B., and Heineman, W. R. Electrochemical biosensors. *Chem. Soc. Rev.*, **2010**, *39*, 1747–63.
- (3) Psoma, S. D., van der Wal, P. D., Frey, O., de Rooij, N. F., and Turner, A. P. F. A novel enzyme entrapment in SU-8 microfabricated films for glucose micro-biosensors. *Biosens. Bioelectron.* **2010**, *26*, 1582–7.
- (4) Scognamiglio, V. Nanotechnology in glucose monitoring: advances and challenges in the last 10 years. *Biosens. Bioelectron.*, **2013**, *47*, 12–25.
- (5) Tang, J., Huang, Y., Liu, H., Zhang, C., and Tang, D. Novel glucometer-based immunosensing strategy suitable for complex systems with signal amplification using surfactant-responsive cargo release from glucose-encapsulated liposome nanocarriers. *Biosens. Bioelectron.*, **2016**, *79*, 508–14.
- (6) Xiang, Y., and Lu, Y. Using personal glucose meters and functional DNA sensors to quantify a variety of analytical targets. *Nat. Chem.*, **2011**, *3*, 697–703.
- (7) Halámková, L., Halánek, J., Bocharova, V., Szczupak, A., Alfonta, L., and Katz, E. Implanted biofuel cell operating in a living snail. *J. Am. Chem. Soc.*, **2012**, *134*, 5040–3.
- (8) Guo, Z., Johnston, W. A., Stein, V., Kalimuthu, P., Perez-Alcala, S., Bernhardt, P. V., and Alexandrov, K. Engineering PQQ-glucose dehydrogenase into an allosteric electrochemical Ca(2+) sensor. *Chem. Commun. (Camb.)*, **2016**, *52*, 485–8.
- (9) Stein, V., and Alexandrov, K. Synthetic protein switches: design principles and applications. *Trends Biotechnol.*, **2010**, *33*, 101–10.
- (10) Tullman, J., Nicholes, N., Dumont, M. R., Ribeiro, L. F., and Ostermeier, M. Enzymatic protein switches built from paralogous input domains. *Biotechnol. Bioeng.* **2015**, *113*, 852–858.
- (11) Igarashi, S., Hirokawa, T., and Sode, K. (2004) Engineering PQQ glucose dehydrogenase with improved substrate specificity. Site-directed mutagenesis studies on the active center of PQQ glucose

dehydrogenase. *Biomol. Eng.*, **2004**, *21*, 81–9.

(12) Wehr, M. C., and Rossner, M. J. Split protein biosensor assays in molecular pharmacological studies. *Drug Discov.*, **2016**, *Today* *21*, 415–429.

(13) Banaszynski, L. A., Liu, C. W., and Wandless, T. J. Characterization of the FKBP.rapamycin.FRB ternary complex. *J.Am.Chem.Soc.* **2005**, *127*, 4715–4721.

(14) Armstrong, V. W., and Oellerich, M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. *Clin. Biochem.*, **2001**, *34*, 9–16.

(15) Zheng, H., Bi, J., Krendel, M., and Loh, S. N. (2014) Converting a binding protein into a biosensing conformational switch using

protein fragment exchange. *Biochemistry*, **2014**, *53*, 5505–14.

(16) Ohmuro-Matsuyama, Y., Chung, C.-I., and Ueda, H. Demonstration of protein-fragment complementation assay using purified firefly luciferase fragments. *BMC Biotechnol.*, **2013**, *13*, 31.

(17) Choi, J. H., Zayats, M., Searson, P. C., and Ostermeier, M. Electrochemical activation of engineered protein switches. *Biotechnol. Bioeng.*, **2016**, *113*, 453–6.

(18) Choi, J. H., and Ostermeier, M. Rational design of a fusion protein to exhibit disulfide-mediated logic gate behavior. *ACS Synth. Biol.*, **2015**, *4*, 400–6.

TOC Graphics

